Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 3, 2016 - Issue 1
Submit an article Journal homepage
780
Views
11
CrossRef citations to date
0
Altmetric
Original Research Articles

Quality of life among pulmonary hypertension patients in Finland

Merja KukkonenDepartment of Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, FinlandCorrespondence[email protected]
,
Airi PuhakkaActelion Pharmaceuticals Sverige AB filial Finland, Espoo, Finland
&
Maija HalmeDepartment of Pulmonary Diseases, Helsinki University Central Hospital, Helsinki, Finland
Article: 26405 | Received 23 Oct 2014, Accepted 27 Feb 2015, Published online: 18 Jan 2016

References

  • Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, etal. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62: D42–50.
  • Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, etal. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl D): D34–41.
  • Svenska PAH-registret. Årsrapport 2013. Available from: http://www.ucr.uu.se/spahr/ [cited 23 October 2014]..
  • Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, etal. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl D): D60–72.
  • Halme M. Pulmonaalihypertension lääkehoito [Medical treatment of pulmonary arterial hypertension. Article in Finnish]. Suomen Lääkärilehti. 2009; 64: 1121–6.
  • Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, etal. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011; 81: 394–401.
  • Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, etal. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005; 6: 92.
  • Chua R, Keogh AM, Byth K, O'Loughlin A. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006; 36: 705–10.
  • Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, etal. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Res Med. 2008; 102: 1431–8.
  • Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. Comparison of cardiac and pulmonary specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011; 38: 608–16.
  • Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014; 29: 178–84.
  • Fernandes C, Martins B, Jardim C, Ciconelli R, Morinaga L, Breda AP, etal. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcome. 2014; 12: 130.
  • Ghofrani HA, Galiè N, Grimminger F, Grünig E, Hubert M, Jing ZC, etal. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369: 330–40.
  • Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004; 43: 1149–53.
  • Yorke J, Corris P, Gaine S, Gibbs JSR, Kiely D, Harries C, etal. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014; 43: 1106–13.
  • Clinical trials.gov. SYMPHONY: a study of macitentan in pulmonary arterial hypertension to validate the PAHSYMPACT. NCT01841762 [last updated 2014 September 18]. Available from: http://clinicaltrials.gov/show/NCT01841762 [cited 14 January 2015].
  • Clinical trials.gov. A pulmonary arterial hypertension study with macitentan to validate the PAH-SYMPACTTM in France, Italy and Spain (ORCHESTRA). NCT02081690 [last updated 2014 August 7]. Available from: http://clinicaltrials.gov/show/NCT02081690 [cited 14 January 2015].
  • Clinical trials.gov. Extension of the psychometric validation study ORCHESTRA in patients with PAH. NCT02112487 [last updated 2014 August 11]. Available from: http://clinicaltrials.gov/show/NCT02112487 [cited 14 January 2015].
  • Ware JE, Sherbourne C. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992; 30: 473–83.
  • Matura LA, McDonough A, Carroll DL. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012; 11: 51–61.
  • Ware JE. User's manual for the SF-36v2 health survey. 81. 2nd ed. Quality Metric, 2007.
  • Sankelo M, Flanagan JA, Machado R, Harrison R, Rudarakanchana N, Morrell N, etal. BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. Hum Mutat. 2005; 26: 119–24.
  • Kahlos K, Halme M, Turpeinen A, Pettersson T, Turanlahti M, Luosujärvi R, etal. Keuhkovaltimoiden verenpainetauti ja krooninen tromboembolinen keuhkoverenpainetauti. Suomen Lääkärilehti. 2013; 68: 2515–20.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.